Locations:
SearchAdvertisement
Improving safety, efficacy and access for emerging therapies
Phase 2 study of parsaclisib with ruxolitinib demonstrates improved efficacy for patients previously treated with ruxolitinib alone
DESTINY-Breast04 study leads to practice-changing findings
Largest real-world cohort of polycythemia vera patients
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Treatment effective post-ruxolitinib failure
Multi-center study indicates benefit is associated with risk stratification and the utilization of radiation therapy
Germline testing of 400 patients shows that more than one in seven have an inherited risk for cancer
Young-onset disease presentation on the rise
How online education is redefining the patient-provider relationship
Bcl-xL inhibitors may help overcome this complication
Advertisement
Advertisement